Comparative Pharmacology
Head-to-head clinical analysis: LEQEMBI IQLIK versus SOLIRIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEQEMBI IQLIK versus SOLIRIS.
LEQEMBI IQLIK vs SOLIRIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Monoclonal antibody targeting aggregated soluble and insoluble forms of amyloid beta, reducing amyloid plaques in the brain.
Soliris (eculizumab) is a monoclonal antibody that specifically binds to complement protein C5, thereby inhibiting its cleavage to C5a and C5b and preventing the formation of the membrane attack complex (MAC). This action blocks terminal complement-mediated inflammation and cell lysis.
Lecanemab (LEQEMBI IQLIK) for Alzheimer disease: 10 mg/kg IV infusion every 2 weeks, diluted in 250 mL saline, administered over approximately 1 hour. Initiate with 1 mg/kg IV on day 0 and 3 mg/kg IV on day 14 for titration, then 10 mg/kg IV every 2 weeks.
600 mg intravenous over 35 minutes weekly for 4 weeks, then 900 mg 1 week later, followed by 900 mg every 2 weeks for paroxysmal nocturnal hemoglobinuria (PNH). For atypical hemolytic uremic syndrome (aHUS): 900 mg intravenous over 35 minutes weekly for 4 weeks, then 1200 mg 1 week later, followed by 1200 mg every 2 weeks.
None Documented
None Documented
Terminal half-life approximately 24.6 days (range 23-27 days) in patients with Alzheimer's disease; supports monthly intravenous dosing.
Terminal elimination half-life: approximately 11.3 ± 3.4 days (range 8–18 days) following biweekly dosing. This supports a dosing interval of every 2 weeks for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Primarily proteolytic catabolism to amino acids; renal elimination of intact drug is negligible (<1%). Biliary/fecal excretion is not a major route.
Eculizumab is not metabolized by cytochrome P450 enzymes; it is degraded via general protein catabolism. Clearance is primarily through the reticuloendothelial system; renal excretion of intact drug is negligible (<1%). No biliary or fecal excretion data are available in humans.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody